News & Events about Guardant Health Inc.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE...
Business Wire
2 months ago
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield, Guardant Healths blood test to screen for colorectal cancer (CRC...
Globe Newswire
2 months ago
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study resultsSermonix anticipates dosing the first patient in first half of 2023 COLUMBUS...
Guardant Health (NASDAQ:GH Get Rating) had its price target trimmed by Piper Sandler from $50.00 to $35.00 in a report published on Friday, The Fly reports. The firm currently has a neutral rating on the stock. GH has been the subject of several other research reports. BTIG Research cut their price ...